The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells

Carcinogenesis

Volumn 29, Issue 3, 2008, Pages 466-472

  Simpkins, Fiona A ^a   Devoogdt, Nick M ^a,b   Rasool, Nabila ^a   Tchabo, Nana E ^a   Alejandro, Emilyn U ^a   Kamrava, Mitchell M R N ^a   Kohn, Elise C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; ELASTASE; NEUTRALIZING ANTIBODY; PROGRANULIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL COUNT; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS;

CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CULTURE MEDIA, CONDITIONED; FEMALE; GENE SILENCING; HUMANS; IMMUNOPRECIPITATION; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; NEUTRALIZATION TESTS; OVARIAN NEOPLASMS; RECOMBINANT PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR;

EID: 40949102655     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm212     Document Type: Article

References (42)

1. Williams,S.E. et al. (2006) SLPI and elafin: One glove, many fingers. Clin. Sci., 110, 21-35.
2. King,A.E. et al. (2003) Differential regulation of secretory leukocyte protease inhibitor and elafin by progesterone. Biochem. Biophys. Res. Commun., 310, 594-599.
3. Zhu,J. et al. (2002) Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell, 111, 867-878.
4. Ding,A. et al. (2005) Induction of macrophage-derived SLPI by Mycobacterium tuberculosis depends on TLR2 but not MyD88. Immunology 116, 381-389.
5. Devoogdt,N. et al. (2003) Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc. Natl Acad. Sci. USA, 100, 5778-5782.
6. Wang,N. et al. (2006) The secretory leukocyte protease inhibitor is a type 1 insulin-like growth factor receptor-regulated protein that protects against liver metastasis by attenuating the host proinflammatory response. Cancer Res., 66, 3062-3070.
7. Jemal,A. et al. (2006) Cancer statistics. CA Cancer J. Clin. 56, 106-130.
8. Bouchard,D. et al. (2006) Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol., 7, 167-174.
9. Hough,C.D. et al. (2001) Coordinately up-regulated genes in ovarian cancer. Cancer Res., 61, 3869-3876.
10. Clauss,A. et al. (2005) The evolution of a genetic locus encoding small serine proteinase inhibitors. Biochem. Biophys. Res. Commun. 333, 383-389.
11. Israeli,O. et al. (2005) In silico chromosomal clustering of genes displaying altered expression patterns in ovarian cancer. Cancer Genet. Cytogenet., 160, 35-42.
12. Shigemasa,K. et al. (2001) Expression of the protease inhibitor antileuko-protease and the serine protease stratum corneum chymotryptic enzyme (SCCE) is coordinated in ovarian tumors. Int. J. Gynecol. Cancer, 11, 454-461.
13. Drapkin,R. et al. (2005) Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res., 65, 2162-2169.
14. Tsukishiro,S. et al. (2005) Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol. Oncol., 96, 516-519.
15. Bingle,L. et al. (2002) The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene. 21, 2768-2773.
16. Hellstrom,I. et al. (2003) The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res., 63, 3695-3700.
17. Bateman,A. et al. (1990) Granulins, a novel class of peptide from leukocytes. Biochem. Biophys. Res. Commun., 173, 1161-1168.
18. Bateman,A. et al. (1998) Granulins: The structure and function of an emerging family of growth factors. J. Endocrinol., 158, 145-151.
19. Jones,M.B. et al. (2003) The granulin-epithelin precursor/ PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer. Clin. Cancer Res., 9, 44-51.
20. Kamrava,M. et al. (2005) Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin-epithelin precursor (GEP), a prosurvival factor for ovarian cancer. Oncogene, 24, 7084-7093.
21. He,Z. et al. (2003) Progranulin is a mediator of the wound response. Nat. Med., 9, 225-229.
22. Gonzalez,E.M. et al. (2003) A novel interaction between perlecan protein core and progranulin: Potential effects on tumor growth. J. Biol. Chem., 278, 38113-38116.
23. Davidson,B. et al. (2004) Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer, 100 2139-2147.
24. Doong,H. et al. (2000) CAIR-1/BAG-3 forms an EGF-regulated ternary complex with phospholipase C-gamma and Hsp70/Hsc70. Oncogene, 19, 4385-4395.
25. Doong,H. et al. (2003) CAIR-1/BAG-3 abrogates heat shock protein-70 chaperone complex-mediated protein degradation: Accumulation of poly-ubiquitinated Hsp90 client proteins. J. Biol. Chem., 278, 28490-28500.
26. Kassis,J.N. et al. (2006) CAIR-1/BAG-3 modulates cell adhesion and migration by downregulating activity of focal adhesion proteins. Exp. Cell Res., 312, 2962-2971.
27. Seemuller,U. et al. (1986) The acid-stable proteinase inhibitor of human mucous secretions (HUSI-I, antileukoprotease). Complete amino acid sequence as revealed by protein and cDNA sequencing and structural homology to whey proteins and Red Sea turtle proteinase inhibitor. FEBS Lett., 199, 43-48.
28. Tanner,M.M. et al. (2000) Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin. Cancer Res., 6, 1833-1839.
29. Courjal,F. et al. (1996) DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours. Br. J. Cancer, 74, 1984-1989.
30. Devoogdt,N. et al. (2004) Secretory leukocyte protease inhibitor in cancer development. Ann. N. Y. Acad. Sci., 1028, 380-389.
31. Wang,Y. et al. (2005) Regulatory effect of e2, IL-6 and IL-8 on the growth of epithelial ovarian cancer cells. Cell Mol. Immunol., 2, 365-372.
32. Xu,L. et al. (2000) Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int. J. Oncol., 16, 445-454.
33. Yoneda,J. et al. (1998) Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J. Natl Cancer Inst., 90, 447-454.
34. Velarde,M.C. et al. (2005) The secretory leukocyte protease inhibitor gene is a target of epidermal growth factor receptor action in endometrial epithelial cells. J. Endocrinol., 184, 141-151.
35. Westin,U. et al. (2002) The presence of elafin, SLPI, IL1-RA and STNFalpha RI in head and neck squamous cell carcinomas and their relation to the degree of tumour differentiation. Mediators Inflamm. 11, 7-12.
36. Jana,N.K. et al. (2005) Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: A role for SLPI in innate mucosal immunity. J. Virol., 79, 6432-6440.
37. Farquhar,C. et al. (2002) Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. J. Infect. Dis. 186, 1173-1176.
38. Pillay,K. et al. (2001) Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. J. Infect. Dis., 183, 653-656.
39. Ashcroft,G.S. et al. (2000) Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat. Med., 6, 1147-1153.
40. Lentsch,A.B. et al. (1999) Secretory leukocyte protease inhibitor in mice regulates local and remote organ inflammatory injury induced by hepatic ischemia/reperfusion. Gastroenterology, 117, 953-961.
41. Devoogdt,N. et al. (2006) The tumor-promoting effect of TNF-alpha involves the induction of secretory leukocyte protease inhibitor. J. Immunol., 177, 8046-8052.
42. Aarbiou,J. et al. (2004) Human neutrophil defensins and secretory leukocyte proteinase inhibitor in squamous metaplastic epithelium of bronchial airways. Inflamm. Res., 53, 230-238.